Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, Thomas F., Zhao, Fangzhu, Huang, Deli, Beutler, Nathan, Burns, Alison, He, Wan-ting, Limbo, Oliver, Smith, Chloe +26 more·2020·Science
DOI 10.1126/science.abc7520

Cited by (1,034)

Items 1,001–1,034 of 1,034

  1. Enhanced protective efficacy of a novel, thermostable, RBD-S2 vaccine formulation against SARS-CoV-2 and its variants
    Nidhi Mittal, Sahil Kumar, Raju S. Rajmani, Randhir Singh, Céline Lemoine, Virginie Jakob, Sowrabha Bj, Nayana Jagannath, Madhuraj Bhat, Debajyoti Chakraborty et al. · 2023 · bioRxiv
  2. Renin-angiotensin-system blockers and IgG antibodies in end-stage renal disease hemodialysis-receiving patients diagnosed with COVID-19 infection
    Sultan A Almdallaleh, Abdulkareem Alsuwaida, Abdulhadi M Altalhi, Dina M. Aljayar, Elzibair E Massad, Mazaheri Hamid, P. Jaganathan, Fadel H Al-Hababi · 2023 · Saudi Medical Journal
  3. No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model
    D. Reed, Anita K. McElroy, Dominique J. Barbeau, Cynthia M. McMillen, N. L. Tilston-Lunel, Sham Nambulli, Emily Cottle, Theron C. Gilliland, Hasala Rannulu, Jeneveve D. Lundy et al. · 2023 · bioRxiv
  4. Evaluation of virus-neutralizing antibody level after novel coronavirus infection COVID-19: development of an instant assay assessing protective antibodies using a pseudovirus-based reaction
    A. А. Funtikov, N. A. Litvinova, Евгений Викторович Зуев, S. Kulemzin, R. R. Shukurov · 2023 · Russian Journal of Infection and Immunity
  5. Identification of conserved linear epitopes in the SARS-CoV-2 receptor-binding region using monoclonal antibodies
    Yujie Yang, Liling Zhou, Chuncong Mo, Longbo Hu, Zhichao Zhou, Ye Fan, Wenkuan Liu, Xiao Li, Rong Zhou, Xingui Tian · 2023 · Heliyon
  6. Covid-19 infection: Successful global spread, challenges to public health surveillance, and lessons learnt
    Ogunkunle Taofik, Bello Surajudeen, Ibraheem M. Rasheedat, Katibi Sherifat, Ibrahim A. Tajudeen, I. Abdulazeez, Olaosebikan Rasaq · 2023 · Journal of Public Health and Epidemiology
  7. Pathogenesis of Breakthrough Infections with SARS-CoV-2 Variants in Syrian Hamsters
    Jessica Plunkard, Kathleen R. Mulka, Rui-Feng Zhou, P. Tarwater, William Zhong, M. Lowman, Amanda Wong, A. Pekosz, J. Villano · 2023 · bioRxiv
  8. An alpaca-derived nanobody recognizes a unique conserved epitope and retains potent activity against the SARS-CoV-2 omicron variant
    N. Modhiran, S. Lauer, A. Amarilla, P. Hewins, Sara Lopes van den Broek, Y. Low, Nazia Thakur, Benjamin Liang, Guillermo Valenzuela Nieto, James Jung et al. · 2022 · bioRxiv
  9. Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
    E. Shipaeva, O. Filon, A. Zintchenko, G. Shipunov, A. Dmitrieva, M. Lemak, S. Grishin, E. I. Trofimets, K. Kryshen, L. Kozlovskaya et al. · 2022 · Biological Products. Prevention, Diagnosis, Treatment
  10. High resolution cryo-EM structures of two potently SARS-CoV-2 neutralizing monoclonal antibodies of same donor origin that vary in neutralizing Omicron variants
    Clayton Fernando Rencilin, M. Y. Ansari, A. Chatterjee, Suprit Deshpande, S. Mukherjee, Randhir Singh, Sowrabha Jayatheertha, Poorvi M. Reddy, Payel Das, Nitin K Hingankar et al. · 2022 · bioRxiv
  11. Laboratory assessment of state of post-vaccination humoral immunity to infections with aerosol transmission mechanism
    A. Ereshchenko, O. Gusyakova · 2022 · Medical alphabet
  12. Recurrence of COVID-19 infection symptoms in short time; reinfection or reactivation? Three cases of three healthcare workers and a literature review
    Nadeem Ahmed, Kinan Abbas, Ebrahim Makhoul, Rudy Deeb, Ashraf Raya, Nagham Khaddour, Faisal N. Redwan · 2022 · Annals of Medicine and Surgery
  13. ELISA on Chip: High throughput antibody profiling using antigen microarrays
    S. Levy, M. A. Alhadi, Aharon Azulay, A. Kahana, N. Bujanover, R. Gazit, M. McGargill, L. Friedman, T. Hertz · 2022 · medRxiv
  14. Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic Nanobody
    D. Dormeshkin, M. Shapira, S. Dubovik, A. Kavaleuski, M. Katsin, A. Migas, A. Meleshko, S. Semyonov · 2022 · bioRxiv
  15. Producción de partículas virales pseudotipadas SARS-CoV-2 para la evaluación de nuevas terapias para COVID-19
    Lucas Etchevers, Paula Silvestrini, Natalia Velázquez, M. E. Baravalle, María Sol Renna, Florencia Martín Olmos, H. Ortega, Belkis E. Marelli · 2022 · FAVE Sección Ciencias Veterinarias
  16. T and B Cells Immune Response and the importance of vaccines Against SARS-CoV-2
    R. Ordoñez, D. Solano, Gustavo Granizo · 2022 · Bionatura
  17. Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection
    A. Adhikari, Arunasingam Abayasingam, C. Rodrigo, David Agapiou, E. Pandžić, Nicholas A. Brasher, Bentotage Samitha Madushan Fernando, Elizabeth Keoshkerian, Hui Li, Ha Na Kim et al. · 2021 · bioRxiv
  18. Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort
    Dominik Menges, K. Zens, T. Ballouz, Nicole Caduff, Daniel Llanas-Cornejo, Hélène E. Aschmann, Anja Domenghino, Céline Pellaton, M. Perreau, C. Fenwick et al. · 2021 · medRxiv
  19. A bacteria-based assay to study SARS-CoV-2 protein-protein interactions
    B. L. Springstein, P. Deighan, G. Grabe, A. Hochschild · 2021 · bioRxiv
  20. Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
    Gonzalo Almanza, V. Kouznetsova, A. Clark, Eduardo Olmedillas, Andrea Castro, I. Tsigelny, Yan Wu, G. Gao, E. Saphire, Aaron F. Carlin et al. · 2021 · bioRxiv
  21. ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants
    J. Seow, C. Graham, Sadie R. Hallett, T. Lechmere, T. Maguire, I. Huettner, D. Cox, R. Roberts, A. Waters, Christopher C. Ward et al. · 2021 · bioRxiv
  22. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2
    Rahul Ukey, N. Bruiners, Hridesh Mishra, P. Mishra, Deborah McCloskey, A. Onyuka, Fei Chen, Abraham Pinter, D. Weiskopf, Alessandro Sette et al. · 2021 · medRxiv
  23. Humoral immune responses against seasonal coronaviruses predict efficiency of SARS-CoV-2 spike targeting, FcγR activation, and corresponding COVID-19 disease severity
    Jose L. Garrido, Matías A. Medina, Felipe Bravo, S. McGee, F. Fuentes, M. Calvo, James Bowman, C. Bahl, M. I. Barria, R. A. Brachman et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  24. SCIGA: Software for large-scale, single-cell immunoglobulin repertoire analysis
    Haocheng Ye, Lin Cheng, B. Ju, Gang Xu, Yang Liu, Shu-Ye Zhang, Li-Fei Wang, Zheng Zhang · 2021 · GigaScience
  25. Broad neutralizing nanobody against SARS-CoV-2 engineered from pre-designed synthetic library
    Qian-Yun Liu, Chen-Guang Cai, Yanyan Huang, Li Zhou, Y. Guan, S. Fu, You-Hsuan Lin, Ting-rui Yang, Xiao-Hua Liang, Nan Wang et al. · 2021 · bioRxiv
  26. Longitudinal observation of antibody responses after SARS-CoV-2 infection at 14 months
    A. Zaidi, P. Dehgani-Mobaraki, N. Yadav, A. Floridi · 2021 · Research Square
  27. Second-Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
    B. Kovačech, L. Fialova, P. Filipcik, R. Škrabana, M. Zilkova, Natalia Paulenka-Ivanovova, A. Kováč, Denisa Palova, Gabriela Paulíkova Rolkova, K. Tomková et al. · 2021 · bioRxiv
  28. Analysis of viral RNA-host protein interactomes enables rapid antiviral drug discovery
    Shao-Jun Zhang, Wen-Ze Huang, L. Ren, Xiaohui Ju, M. Gong, Jian Rao, Lei Sun, Pan Li, Q. Ding, Jian-Wei Wang et al. · 2021 · bioRxiv
  29. Impact of the SARS-CoV-2 S-protein G476S mutation on the interaction with human ACE-2 receptor and neutralizing antibodies
    A. Kwarteng, Ebenezer Asiedu, A. Sylverken, A. Larbi, P. Twumasi · 2021 · Research Square
  30. A Single Drop of Fingerstick Blood for Quantitative Antibody Response Evaluation After SARS-CoV-2 Vaccination
    Jin-Wei Du, Da-Yu Zhang, Hannah E. May, Yulia Loginova, E. Chu, R. Madej, Chuan-Yi M. Lu, J. Pathakamuri, D. Kuebler, J. Neves et al. · 2021 · medRxiv
  31. SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses
    R. Suhandynata, N. Bevins, J. Tran, De-Li Huang, M. Hoffman, Kyle Lund, M. Kelner, R. Mclawhon, S. Gonias, D. Nemazee et al. · 2021 · medRxiv
  32. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2
    Huibin Lv, O. Tsang, Ray T. Y. So, Yi-Quan Wang, M. Yuan, Hejun Liu, Garrick K. Yip, Q. Teo, Yihan Lin, Wei-Wen Liang et al. · 2021 · bioRxiv
  33. Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies
    David B. Langley, Daniel Christ · 2021
  34. In-Vitro Fluorescence Microscopy Studies Show Retention of Spike-Protein (SARS-Cov-2) on Cell Membrane in the Presence of Amodiaquin Dihydrochloride Dihydrate Drug
    P. Mondal, S. Mandal · 2021 · bioRxiv